Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Metastatic Melanoma
Related studies linked through entity extraction aliases.
Multicenter Tissue Registry in Melanoma
- Status
- UNKNOWN
- Phase
- N/A
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Status
- RECRUITING
- Phase
- PHASE3
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
- Status
- WITHDRAWN
- Phase
- PHASE1
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
- Status
- TERMINATED
- Phase
- PHASE1
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma
- Status
- UNKNOWN
- Phase
- N/A
A Study of LN-144 in People With Metastatic Melanoma to the Brain
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
- Status
- RECRUITING
- Phase
- PHASE1
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
- Status
- COMPLETED
- Phase
- N/A
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
- Status
- RECRUITING
- Phase
- PHASE1
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
- Status
- UNKNOWN
- Phase
- N/A
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
- Status
- AVAILABLE
- Phase
- N/A
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
- Status
- TERMINATED
- Phase
- PHASE1
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE1